# Effects of DES Platforms on Markers of Endothelial Damage and Inflammation

Study · id `cardio:ct-nct01489202` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01489202](<https://clinicaltrials.gov/study/NCT01489202>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01489202

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT01489202. Randomized; single masking; primary purpose diagnostic. Start 2014-09 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT01489202, source copy `cardio:ctgov-nct01489202-2013-03-07`, retrieved 2026-10-26)
- Start date: 2014-09 (registry gives no type) (ClinicalTrials.gov record NCT01489202, source copy `cardio:ctgov-nct01489202-2013-03-07`, retrieved 2026-10-26)
- Primary completion: 2015-12 (anticipated) (ClinicalTrials.gov record NCT01489202, source copy `cardio:ctgov-nct01489202-2013-03-07`, retrieved 2026-10-26)
- Completion: 2016-12 (anticipated) (ClinicalTrials.gov record NCT01489202, source copy `cardio:ctgov-nct01489202-2013-03-07`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT01489202, source copy `cardio:ctgov-nct01489202-2013-03-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01489202-2013-03-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of DES Platforms on Markers of Endothelial Damage and Inflammation
- Acronym: PLATFORM
- Condition: Coronary Artery Disease
- Intervention (Device): platinum chromium everolimus-eluting stent
- Intervention (Device): cobalt chromium everolimus-eluting stent
- Lead sponsor: University of Roma La Sapienza
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: University of Roma La Sapienza (`cardio:org-university-of-roma-la-sapienza`)

## Provenance

Content hash: bc552f1baeaa9ef95c1dd6258e114ca896b1756b62dea93ed792ac8ca8e57fa9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
